<DOC>
	<DOCNO>NCT00920699</DOCNO>
	<brief_summary>To establish tolerability treatment 600 , 1200 2400 mg per day coenzyme Q10 pre-manifest participant carry CAGn expansion Huntington 's Disease ( HD ) .</brief_summary>
	<brief_title>Study PRE-manifest Huntington 's Disease Coenzyme Q10 ( UbiquinonE ) Leading Preventive Trials ( PREQUEL )</brief_title>
	<detailed_description>secondary objective : 1 . To assess change baseline 20 week biomarkers oxidative stress ( 8OHdG 8OHrG ) DNA repair mechanism ( OGG1 ) pre-manifest participant treat 600 , 1200 2400 mg per day CoQ10 . 2 . To assess dose-response relationship CoQ10 dosages 600 , 1200 2400 mg per day 8OHdG/8OHrG OGG1 . 3 . To assess serum level CoQ10 600 , 1200 2400 mg pre-manifest participant relationship 8OHdG/8OHrG OGG1 . 4 . To assess feasibility implement preventive therapeutic trial pre-manifest population . 5 . To assess utility stability clinical measure HD , social relation , behavior employment pre-manifest sample enrol treatment trial .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Participants positive CAGn expansion Huntingtin gene ( &gt; 36 repeat ) premanifest virtue score 3 less diagnostic confidence level ( Question 17 UHDRS ) Participants receive genetic test prior enrollment standard premanifest test protocol . 18 year age old . Concomitant medication permit exception CoQ10 , creatine &gt; 5g/day warfarin . History intolerability CoQ10 . CoQ10 use within 60 day prior randomization . Unstable medical psychiatric illness ; Substance abuse within one year baseline visit . Pregnancy , breastfeed lack reliable contraception woman childbearing age . Subjects know allergy FD &amp; C # 6 yellow food coloring .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>